ASX lister raises $121m with Lander & Rogers' help

The equity raising involves a $101m placement and a $20m entitlement offer

ASX lister raises $121m with Lander & Rogers' help

Lander & Rogers has assisted ASX-listed biotech company Clarity Pharmaceuticals with a $121m equity raise.

The funding effort was split into a $101m placement and an entitlement offer to qualified shareholders that generated $20m.

According to the firm, this is Clarity's first capital raising since its $92m IPO in 2021.

The proceeds from the raise will back R&D efforts as well as clinical trials of Clarity’s therapeutic and diagnostic products in Australia and the US.

“Radiopharmaceutical companies have been at the centre of some of the most significant biotech deals over the last 2-3 years”, Lander & Rogers co-lead partner David Morris said. “Demand for new drugs and diagnostics continues to grow, and companies like Clarity are innovating at a remarkable pace, which is fuelling interest from investors. We anticipate considerable deal activity in this fast-growing and rapidly consolidating sector in the year ahead”.

Morris led the Lander & Rogers team alongside David Tink and Simon Davidson. They worked  with lawyers Edison Ponari and Annabelle Gray.

Recent articles & video

Thomson Geer partner on the biggest impact of the Bruce Lehrmann defamation ruling

Federal Court rules in ASIC's favour against Cigno Australia, BSF Solutions

Senior appointments strengthen CBP offerings

Legal orgs team up to aid community legal centres

HSF environment, planning and communities group partners with CEIG on report

New metric developed to assess socioeconomic challenges of US law school applicants

Most Read Articles

NSW Supreme Court sets trial date for landmark strip search class action

K&L Gates Advises Centuria on acquisition of massive glasshouse in Victoria

Hall & Wilcox assists Tobii Dynavox to acquire Link Assistive for $13m

Pearce IP's AU litigation head shares the most important lesson she learned from her old job